# References 

**R1**: Sharpe, M., Jarvis, B., & Goa, K. L. (2001). Telmisartan. Drugs, 61(10), 1501–1529. https://doi.org/10.2165/00003495-200161100-00009

**R2**: Hamilton-Craig, I., Kostner, K., Colquhoun, D., & Woodhouse, S. (2010). Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vascular health and risk management, 6, 1023–1037. https://doi.org/10.2147/VHRM.S13496

**R3**: Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., Luecke, S., Phebus, L. A., Bymaster, F. P., & Paul, S. M. (2001). Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proceedings of the National Academy of Sciences, 98(25), 14669–14674. https://doi.org/10.1073/pnas.251341998

**R4**: Schwartzkopff, B., Brehm, M., Mundhenke, M., & Strauer, B. E. (2000). Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension, 36(2), 220–225. https://doi.org/10.1161/01.hyp.36.2.220

**R5**: Ti Yin, Shu-Chen Kuo, Yea-Yuan Chang, Yung-Tai Chen, Kai-Wei Katherine Wang, Verapamil Use Is Associated With Reduction of Newly Diagnosed Diabetes Mellitus, The Journal of Clinical Endocrinology & Metabolism, Volume 102, Issue 7, 1 July 2017, Pages 2604–2610, https://doi.org/10.1210/jc.2016-3778

**R6**: Kranjec, I., Cerne, A., & Noc, M. (2008). Ephedrine-Induced acute myocardial infarction in a young athlete: a case of thrombus management. Angiology, 60(2), 254–258. https://doi.org/10.1177/0003319707310280

**R7**: Li, W. X., Li, W., Cao, J. Q., Yan, H., Sun, Y., Zhang, H., Zhang, Q., Tang, L., Wang, M., Huang, J. F., & Liu, D. (2016). Folate Deficiency Was Associated with Increased Alanine Aminotransferase and Glutamyl Transpeptidase Concentrations in a Chinese Hypertensive Population: A Cross-Sectional Study. Journal of nutritional science and vitaminology, 62(4), 265–271. https://doi.org/10.3177/jnsv.62.265

**R8**: Chen, L., So, W. Y., Li, S. Y., Cheng, Q., Boucher, B. J., & Leung, P. S. (2015). Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets. Molecular and cellular endocrinology, 404, 56–66. https://doi.org/10.1016/j.mce.2015.01.029

**R9**: Veronese, N., Koyanagi, A., Stubbs, B., Solmi, M., Fornaro, M., Fernandes, B. S., Mueller, C., Thompson, T., Carvalho, A. F., & Maggi, S. (2018). Aspirin and incident depressive symptoms: A longitudinal cohort study over 8 years. International journal of geriatric psychiatry, 33(2), e193–e198. https://doi.org/10.1002/gps.4767

**R10**: Karsan, N., Bose, R. P., & Goadsby, P. J. (2024). Paranoid psychosis after a single parenteral dose of indomethacin administered for headache diagnosis: A case and review of the literature. Cephalalgia Reports, 7. https://doi.org/10.1177/25158163241230685

**R11**: Frampton, J. E., & Peters, D. H. (1995). Ramipril. Drugs, 49(3), 440–466. https://doi.org/10.2165/00003495-199549030-00008

**R12**: Prince, J. B., Wilens, T. E., Biederman, J., Spencer, T. J., Millstein, R., Polisner, D. A., & Bostic, J. Q. (2000). A Controlled Study of Nortriptyline in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 10(3), 193–204. https://doi.org/10.1089/10445460050167304

**R13**: Keating, G. M., & Lyseng-Williamson, K. A. (2005). Tolcapone. CNS Drugs, 19(2), 165–184. https://doi.org/10.2165/00023210-200519020-00006

**R14**: Durif, F., Debilly, B., Galitzky, M., Morand, D., Viallet, F., Borg, M., Thobois, S., Broussolle, E., & Rascol, O. (2004). Clozapine improves dyskinesias in Parkinson disease. Neurology, 62(3), 381–388. https://doi.org/10.1212/01.wnl.0000110317.52453.6c

**R15**: Cheer, S. M., & Wagstaff, A. J. (2004). Quetiapine. CNS Drugs, 18(3), 173–199. https://doi.org/10.2165/00023210-200418030-00004

**R16**: Dennis A Popp, Thomas F Tse, Suresh D Shah, William E Clutter, Philip E Cryer; Oral Propranolol and Metoprolol Both Impair Glucose Recovery from Insulin-induced Hypoglycemia in Insulin-dependent Diabetes Mellitus. Diabetes Care 1 May 1984; 7 (3): 243–247. https://doi.org/10.2337/diacare.7.3.243

**R17**: Robertson, J., Raizer, J., Hodges, J. S., Gradishar, W., & Allen, J. A. (2018). Risk factors for the development of paclitaxel‐induced neuropathy in breast cancer patients. Journal of the Peripheral Nervous System, 23(2), 129–133. https://doi.org/10.1111/jns.12271

**R18**: Yapar, S., & Bolat, N. (2024). Tics induced by mirtazapine in an adolescent. Clinical Psychopharmacology and Neuroscience. https://doi.org/10.9758/cpn.24.1211

**R19**: Nissen SE, Wolski K. Rosiglitazone Revisited: An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality. Arch Intern Med. 2010;170(14):1191–1201. doi:10.1001/archinternmed.2010.207

**R20**: Liehr J.G. (2000). Is Estradiol a Genotoxic Mutagenic Carcinogen?. Endocrine Reviews, Volume 21, Issue 1, 1 February 2000, Pages 40–54, https://doi.org/10.1210/edrv.21.1.0386

**R21**: Torres, C. G., Iturriaga, M. P., & Cruz, P. (2021). Hormonal carcinogenesis in canine mammary cancer: Molecular mechanisms of estradiol involved in malignant progression. Animals, 11(3), 608. https://doi.org/10.3390/ani11030608

**R22**: Quann, E. J., Khwaja, F., Zavitz, K. H., & Djakiew, D. (2007). The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer research, 67(7), 3254–3262. https://doi.org/10.1158/0008-5472.CAN-06-3657

**R23**: Palma, J., Martinez, J., Vernetti, P. M., Ma, T., Perez, M. A., Zhong, J., Qian, Y., Dutta, S., Maina, K. N., Siddique, I., Bitan, G., Ades‐Aron, B., Shepherd, T. M., Kang, U. J., & Kaufmann, H. (2022). mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double‐Blind, Placebo‐Controlled Futility Trial and 1‐Year Biomarker Longitudinal Analysis. Movement Disorders, 37(4), 778–789. https://doi.org/10.1002/mds.28923

**R24**: Napolitano, M., Costa, L., Palermo, R., Giovenco, A., Vacca, A., & Gulino, A. (2011). Protective effect of pioglitazone, a PPARγ ligand, in a 3 nitropropionic acid model of Huntington's disease. Brain research bulletin, 85(3-4), 231–237. https://doi.org/10.1016/j.brainresbull.2011.03.011

**R25**: Sidhu, G., & Sapra, A. (2023). Pravastatin. In StatPearls. StatPearls Publishing.

**R26**: Wang, X., Wang, J., Yu, Y., Ma, T., Chen, P., Zhou, B., & Tao, R. (2017). Decitabine inhibits T cell proliferation via a novel TET2-dependent mechanism and exerts potent protective effect in mouse auto- and allo-immunity models. Oncotarget, 8(34), 56802–56815. https://doi.org/10.18632/oncotarget.18063

**R27**: René Klinkby Støving, MECHANISMS IN ENDOCRINOLOGY: Anorexia nervosa and endocrinology: a clinical update, European Journal of Endocrinology, Volume 180, Issue 1, Jan 2019, Pages R9–R27, https://doi.org/10.1530/EJE-18-0596

**R28**: Orphanet: Argininosuccinic aciduria. (n.d.). https://www.orpha.net/en/disease/detail/23

**R29**: Canreonato potásico | Asociación Española de Pediatría (2020) . Available at: https://www.aeped.es/comite-medicamentos/pediamecum/canreonato-potasico.

**R30**: Esteban-Zubero, E., López-Pingarrón, L., Alatorre-Jiménez, M. A., Ochoa-Moneo, P., Buisac-Ramón, C., Rivas-Jiménez, M., Castán-Ruiz, S., Antoñanzas-Lombarte, Á., Tan, D. X., García, J. J., & Reiter, R. J. (2017). Melatonin's role as a co-adjuvant treatment in colonic diseases: A review. Life sciences, 170, 72–81. https://doi.org/10.1016/j.lfs.2016.11.031

**R31**: da Silva, J. L., Barbosa, L. V., Pinzan, C. F., Nardini, V., Brigo, I. S., Sebastião, C. A., Elias-Oliveira, J., Brazão, V., Júnior, J. C. D. P., Carlos, D., & Cardoso, C. R. B. (2023). The Microbiota-Dependent Worsening Effects of Melatonin on Gut Inflammation. Microorganisms, 11(2), 460. https://doi.org/10.3390/microorganisms11020460

**R32**: Vidal, V., García, S., Martínez, P., Corrales, A., Flórez, J., Rueda, N., Sharma, A., & Martínez-Cué, C. (2012). Lack of behavioral and cognitive effects of chronic ethosuximide and gabapentin treatment in the Ts65Dn mouse model of Down syndrome. Neuroscience, 220, 158–168. https://doi.org/10.1016/j.neuroscience.2012.06.031

**R33**: S. Pushpakom, F. Iorio, P. A. Eyers, K. J. Escott, S. Hopper, A. Wells, A. Doig, T. Guilliams, J. Latimer, C. McNamee, A. Norris, P. Sanseau, D. Cavalla and M. Pirmohamed, "Drug repurposing: progress, challenges and recommendations," Nature Reviews Drug Discovery, vol. 18(1), p. 41–58, 2018. 